Telemedicine Abortion, Explained: The Ms. Q&A with Choix’s Cindy Adam

PUBLISHED 10/24/2022 by

As abortion bans mount in states across the country in the wake of the Supreme Court’s overturning of Roe v. Wade, abortion seekers in states where the procedure is banned are increasingly turning to online telemedicine providers.

“It really helps to alleviate the stress and the barriers that come with accessing such a highly stigmatized and politicized form of care, even in the states where abortion care remains legal,” said Cindy Adam, co-founder and CEO of Choix, of telemedicine abortion. “It puts that power to decide back into the hands of the person seeking care.”

Doctors on Dobbs: Abortion Providers Bear Witness to the Devastating Effects of Roe’s Overturn

PUBLISHED 10/24/2022 by

Abortion providers bear witness to the immediate and devastating effects of the Supreme Court’s decision to overturn Roe.

“It has become devastating to practice medicine,” said Dr. Ellie Ragsdale, an ob-gyn who specializes in high-risk obstetrics and fetal therapy at an academic medical center in Cleveland. “You come to work every day and hope that the decisions you make are the best decisions for your patients, and that those decisions don’t land you in jail.”

Abortion Bans Are Already Affecting Young Women’s Personal and Professional Plans

PUBLISHED 10/24/2022 by

A significant portion of young women are already making plans about where they are willing to live and work based on whether abortion is protected or banned in states, according to new Ms. magazine and Feminist Majority Foundation (FMF) polling by Lake Research Partners across the nine battleground states of Arizona, Florida, Georgia, Nevada, New Hampshire, North Carolina, Ohio, Pennsylvania and Wisconsin.

Rage, Resistance and Feminist Art: The Ms. Q&A With Jennie Carr

PUBLISHED 10/22/2022 by

This summer, artist Jennie Carr launched a series of prints, fueled by the rage and sorrow she felt about the overturning of Roe and the loss of federal abortion rights. Now, her pop art prints are available for purchase. The prints range from $30 to $75, and a large portion of the proceeds will be donated back to Ms. magazine to fuel our feminist reporting, rebelling and truth-telling.

Empowered: Women Tell Family Court Judges of Experiences With Coercive Control Using New Domestic Abuse Law

PUBLISHED 10/21/2022 by

Connecticut’s new Jennifers’ Law, which went into effect last October and expanded domestic abuse to include coercive control, addresses the way perpetrators weaponize the court system.

“We’ve faced trauma and been dismissed in our marriages—then we’ve seen the truth dismissed in court. We tell people to leave an abusive marriage and go to get help and be protected, but then the judicial system has to step up to protect us. I hope women hear our stories and are empowered to speak up about Jennifers’ Law too.”

Weekend Reading on Women’s Representation: Likely Demographic Changes in the 118th Congress; Could Another Woman Replace Liz Truss?

PUBLISHED 10/21/2022 by

Weekend Reading for Women’s Representation is a compilation of stories about women’s representation. 

This week: likely demographic changes in the 118th Congress; firsthand stories from women in Minnesota politics on the barriers they experience as women candidates; could another woman replace Liz Truss? ;and more

‘I’m This. I’m That. I’m Many Things’: Pratibha Parmar on Andrea Dworkin and ‘My Name Is Andrea’

PUBLISHED 10/21/2022 by

Pratibha Parmar’s 2022 film about Andrea Dworkin brought both pushback and praise within feminist and queer communities. In this Q&A, Parmar shares her thoughts on reactions to the film but also about her interest in Dworkin.

“There is an arc between generations of female artists’ protesting violence against women. And I want Andrea’s voice to be part of the conversation on its own terms and in its complexity.”

Citizen Petition to FDA Requests Lifting Restrictions on Mifepristone for Miscarriage Use

PUBLISHED 10/20/2022 by

Mifepristone is highly effective at treating incomplete miscarriages, but patients often cannot get the medication because the FDA tightly regulates the drug as an abortion medication. As a result, the most commonly used medical protocol for miscarriage management today is misoprostol alone. But, research shows that the combination of mifepristone and misoprostol is faster and more effective for miscarriage care as well as less painful than misoprostol alone.

A new citizen petition asks the FDA to modify the drug’s label to add an indication for miscarriage treatment and to remove requirements that clinicians and pharmacies be certified to prescribe and distribute the drug.